In order to facilitate analysis of the complex immune response to cancer cells, a well-defined tumor model system has been established in our group. In this model the metastatic mouse breast cancer 4T1, transfected with the viral protein hemagglutinin (4T1-HA) as a surrogate tumor antigen, is used. The transfer of the viral HA gene provides a tumor that is much more immunogenic, due to response by CD 8 cytotoxic T cells of the mouse to the viral protein. In addition transgenic mice have been generated where the T cell receptor (TCR) transgene specifically recognizes a single dominant peptide of the viral HA protein (TCR-HA), thus allowing for this antigen-specific T cell population to be accurately followed and monitored in vivo. These mice have been crossed onto strains which lack some of the cytotoxic effector molecules of T cells such as perforin and FasL important for killing tumor cells in vitro. More recently we have used a Nanog-promoter-driven green fluoresence construct to mark 4T1.2-HA breast carcinoma cells with a more cancer """"""""stem cell"""""""" phenotype. Nanog is an embryonic transcription factor that maintains cells in a more primitive pluripotent state. Preliminary data suggest that the 4T1.2-HA-Nanog>GFP+ cells have many characteristics of cancer stem cells both in vitro and in vivo. We now have the ability, using these cells, to analyze how small subpopulations of cancer stem cells may respond to immune-mediated cytotoxic effects as well as standard chemotherapies and molecular targeted therapies, and compare their responses to the bulk cancer cell population. We are extending the Nanog-GFP system in an attempt to isolate cancer stem-cell like populations from various human breast carcinoma cell lines including SUM159 cells, generally regarded as human """"""""triple-negative"""""""" breast cancer cells.
|Pellom Jr, Samuel Troy; Dudimah, Duafalia Fred; Thounaojam, Menaka Chanu et al. (2015) Modulatory effects of bortezomib on host immune cell functions. Immunotherapy 7:1011-22|
|Shanker, Anil; Pellom Jr, Samuel T; Dudimah, Duafalia F et al. (2015) Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res 75:5260-72|
|Weiss, Jonathan M; Subleski, Jeff J; Back, Tim et al. (2014) Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/?CD40 therapy. J Immunol 192:5821-9|
|Mathews, Lesley A; Keller, Jonathan M; Goodwin, Bonnie L et al. (2012) A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells. J Biomol Screen 17:1231-42|
|Zaritskaya, Liubov; Shurin, Michael R; Sayers, Thomas J et al. (2010) New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines 9:601-16|
|Shanker, Anil; Brooks, Alan D; Jacobsen, Kristen M et al. (2009) Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69:6615-23|
|Salcedo, Rosalba; Hixon, Julie A; Stauffer, Jimmy K et al. (2009) Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 182:4328-38|